FMO5 and hypertensive disorder: While direct evidence for a role for ROS and NADPH oxidase is currently lacking, the fact that oxidative stress has been shown to be present in hypertension, albeit with different end points, raises the possibility that ROS and NADPH oxidases may play a role in rarefaction.